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Systemic sclerosis and other connective 
tissue diseases are thought to be rare in 
Nigerians and are not common causes of 
heart failure compared to hypertensive 
heart disease. The presence of cardiac 
involvement in a patient with systemic 
sclerosis generally portends poor 
outcome. We therefore present a report of 
congestive cardiac failure in a patient 
with systemic sclerosis. 
METHODS 
The case records of a patient with 
systemic sclerosis and congestive cardiac 
failure and a review of the literature 
utilizing Medline, PubMed and google 
search engines was utilized. 
RESULT 
A 68 year old female with ACR criteria for 
the diagnosis of SSe presented in CCF. 
Cardiac evaluation revealed findings 
suggestive of primary cardiac disease of 
SSe. The presence ofCCF in patients with 
SSe is a poor prognostic marker and 
cause of mortality and morbidity, 
CONCLUSION 
Early detection of cardiovascular 
manifestations should be a priority in 
systemic sclerosis. 7b the best of our 
knowledge, CCF due to SSe has not been 
reported in Nigerians. 
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INTRODUCTION 
Systemic sclerosis (SSe) is a chronic 
autoimmune multi-systemic disorder of 
unknown etiology characterized by the 
presence of fibrosis of the skin and 
visceral organs, predominantly small 
vessel disease and a systemic 
inflammatory process.1 The disease is 
characterized by thickening of the skin 
(scleroderma) and distinctive 
involvement of multiple internal 
organs, most notably the lungs, 
gastrointestinal tract, heart, and 
kidneys1'2• 
The increasing morbidity, mortality and 
reduced life expectancy accompanying 
SSe has consistently been associated 
with the cardio-pulmonary 
complications of pulmonary arterial 
hypertension, interstitial lung 
disease(ILD) and cardiac function 
impairmene. Consequently lung and 
heart involvement in SSe are the major 
poor prognostic factors. 1'3 
This recognition of cardio-pulmonary 
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involvement in the morbidity and 
mortality of SSe is demonstrated by the 
findings of Al-Dhaheret al3 in a 
Canadian study which reported worse 
survival rates for patients with cardiac 
disease and hypertension, with 
pulmonary arterial hypertension, renal 
complications, ILD and cardiac 
complications as the major primary 
causes of death. 3 
The prevalence and epidemiology of 
cardiac involvement and cardiac 
dysfunction in SSe and its impact on 
mortality and morbidity has been the 
subject of interest in recent studies.4 
This interest has been promoted by the 
contribution of cardiac-related deaths 
from primary cardiac causes (fibrosis) 
which is estimated at 15% of all SSe 
deaths. 4The need to improve the 
persistent mortality rates from cardiac 
disease in contrast to the reduced death 
rates from renal complications has also 
stimulated research on the cardiac 
impact of SSe. 3-6 
The heart involvement in SSe is either 
primary, related to myocardial fibrosis, 
or secondarily from pulmonary arterial 
hypertension (PHT) and systemic 
hypertension 1'4'5'7'8. 
The consequences of direct cardiac 
involvement in SSe are Arrhythmias 
and conduction defects from reentry, 
inflammation and local fibrosis which 
may lead to palpitation and syncope. 
Other effects are pericardia! disease 
from inflammation and effusion which 
leads to dyspnea and chest pain; and 
direct myocardial involvement with 
myocarditis and fibrosis which leads to 
congestive cardiac failure (CCF)1'4'5•7•8•9·• 
The key elements of cardiac 
involvement which have been 
implicated as risk factors for and 
predictors of morbidity in SScare left 
ventricular (LV) systolic dysfunction, 
left axis deviation and pericardia! 
involvement with large effusion. 4-8'9 
These key elements and manifestations 
of primary cardiac disease in SSe are 
known to occur at various points in the 
course of SSe disease. As a result, the 
opinion that cardiac complications are 
only associated with long-standing skin 
involvement are no longer valid as 
myocarditis, sudden death or cardiac 
arrhythmias, may occur during the 
early stage of the disease. 4-8'9 
It is known that LV systolic dysfunction 
related to myocardial fibrosis and 
myocarditis resulting in CCF may 
complicate the clinical course of SSe 
patients. The diagnosis of CCF may 
however be missed by clinician's as the 
features can be disguised by the 
respiratory and secondary cardiac 
causes of dyspnea 4'8-11 
It is thus important to ensure adequate 
evaluation in SScpatients with cardiac 
failure symptoms, in order to avoid a 
misdiagnosis ofCCF from direct cardiac 
involvement as corpulmonalesecondary 
pulmonary arterial hypertension or 
systemic hypertension from renal 
disease10'11• 
The importance of avoiding this pitfall 
in patients with SSe is the fact that 
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treatment options for CCF from primary 
cardiac and secondary causes differ, as 
immunosuppressive and steroids are 
indicated in patients with CCF from 
myocarditis4'8• 
Sse is thought to be rare among Nigerians and 
even Africans12-14 though recent studies have 
shown that it is not as rare as previously 
thought.14-16ln settings like Nigeria where SSe 
is considered a rarity the diagnosis of CCF 
from primary cardiac disease is therefore more 
likely to be over looked and under diagnosed. 
The objective of this report is to present a case 
ofCCF in a patient with SSe in Nigeria in order 
to increase the knowledge and index of 
suspicion as diagnostic facilities are more 
available. 
CASE REPORT 
Mrs 0. J. a 63yr old petty trader presented 
with three months history of bilateral leg 
swelling, dyspnoea at rest; paroxysmal 
nocturnal dyspnoea, orthopnea, palpitation, 
unproductive cough and right hypochondria! 
pain. She was neither a known hypertensive 
nor diabetic. Six months earlier, she had 
noticeda non-pruritic rash in the arms which 
later spread to involve the axilla, shoulders, 
neck, face, and the anterior chest wall with 
areas ofhypo pigmentation over the face, neck 
and the upper trunk. There was no loss of 
sensation in the hypopigmented regions. 
On examination, she had salt and pepper rash 
on the face, neck, arms and upper trunk. There 
were hypopigmented patches on the chest with 
alopecia areata. (Figure 1) 
She was in respiratory distress with a pulse 
rate off 110beats per minute and thickened 
arterial wall but no locomotor brachialis. 
Blood pressure was 110/70 mmHg and the 
jugular venous pressure(JVP) was raised to 
angle ofthejaw at 12cm/H20. The precordium 
was normoactive with the apex beat located at 
the fifth left intercostal space, lateral to mid 
clavicular line without an apical and left 
parasternal heave. There was S3 gallop 
rhythm with grade 3/6 non radiating apical 
midsystolic murmur. 
The electrocardiogram showed sinus 
tachycardia with occasional Premature 
Ventricular Complexes and inferolateral 
ischemia.- Figure 2 
Echocardiography showed dilatation of all 
four chambers with an Ejection fraction of 
38%. There was grade III diastolic 
dysfunction, moderate mitral regurgitation, 
dilated pulmonary artery and thickened 
pericardium. These findings indicated marked 
systolic dysfunction and diastolic impairment 
of restrictive pattern. (Figure 3) 
Her ESR was 44mmlhr while Anti-nuclear 
antibody and anti-topoisomerase antibody 
were also negative. The Pulmonary function 
test showed a restrictive pattern. 
Serum electrolytes, renal function indices, 
liver enzymes and lipid profile were with 
normal limits, while serum uric acid was 
elevated 801umol/l. 
A Skin biopsy was taken for histology and this 
revealed a section of skin tissue with atrophic 
epidermis. The dermis was thickened by broad 
bands of hyalinized collagen bundles that 
appeared loose in the papilary dermis and 
compact in the reticular dermis with extension 
to the subcutaneous tissue. The dermal 
appendages also appeared atrophic. There 
were a few blood vessels with thickened wall 
and collagen deposit around them. 
The findings were consistent with SSe as the 
patient's clinical features of Proximal diffuse 
(truncal) sclerosis (skin tightness, thickening, 
non-pitting induration) and evidence of 
pulmonary restriction and fibrosis met the 
American College of Rheumatology (ACR) 
criteria for the diagnosis ofScleroderma.17 
The patient was treated for CCF with 
frusemide, spironolactone, lisinopril, digoxin, 
prednisolone, wafarin and enoxparin. She 
however developed bleeding from the skin 8 
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involvement in SSe is considered a serious 
consequence as the presence of cardiac 
involvement generally signifies a poor 
outcome for the patient;1'4'8'18especially as 
individuals who develop clinically apparent 
myocardial manifestations are recognized to 
be at greater risk of clinical deterioration8'9'18• 
Therefore the monitoring of myocardial 
involvement represents an important aspect of 
their disease managemene·4• 
The cardiac involvement in SSe can generally 
be divided into direct cardiac effects and the 
indirect effect of other organ involvement such 
as pulmonary hypertension and renal 
crisis4'8'18• The direct cardiac effects can involve 
the myocardium, coronary arteries, 
pericardium and the conduction system4'5'8'18• 
Vlachoyiannopouloset ar9in a review article 
retrospectively analyzed the clinical files of 
254 patients over 4 years. They estimated the 
mortality rate to be 2% per year, and the 
incidence of cardiac disease to be between 7% 
in lcSSc and 21% in dcSSc patients. Similar 
findings have been reported in an African 
population by Ilovi and Oyoo15 in Kenya who 
found a prevalence of 22% for cardiac 
involvement in patients with SSe. It has also 
been suggested that the use of nuclear 
cardiology imaging will reveal a higher 
estimate of cardiac involvement in patients 
withSsc7• 
In the majority of SSe patients, cardiac 
manifestations may remain subclinical and 
are usually undetected4'8• These early cardiac 
manifestations can then progress silently to 
myocardial fibrosis and may also manifest as 
arrhythmia, left and right heart dysfunction 
and cardiac failure, pericardia! disease, 
valvular disease and sudden death. 4'5'8 
The relatively short course of 6months from 
the onset of disease to the presentation with 
CCF and the resultant mortality in our patient 
exemplifies the early and silent onset of 
cardiac complications of SSe. In addition the 
adverse outcome of mortality which is 
associated with cardiac manifestations in 
SSc1'3'4 is also illustrated by the presented 
index case. 
The presentation and outcome of our reported 
case also indicates the variability of the 
clinical course in SSe as well as the connection 
of skin sclerosis with cardiac disease 4'8• 
The patient in our report presented with 
arrhythmias (PVCs), cardiac ischemia, 
pericardia! disease and ventricular 
dysfunction which are all features of primary 
cardiac involvement thus strengthening the 
diagnoses of CCF in this patient rather than a 
secondary event such as cor-pulmonale. 
Kane et ae0 studied 29 patients with systemic 
scleroderma who underwent a complete 
cardiovascular work-up including physical 
examination, electrocardiogram, chest x-ray 
and Doppler-echocardiogram. Hypertension 
was observed in 20.7% of the patients while 
heart disease was observed in 14 (48.3%) of 
patients. Myocardial disease was the most 
frequent form of cardiac disease in 37.9% of the 
patients followed by pericardia! disease and 
valve disease seen in 13.8% of the cases each. 
Rhythm and conduction disorders were found 
in 2 (6.9%) and 8 (27.6%) of the patients 
respectively. 
Baduiet al21in a study based on non-invasive 
cardiac evaluation among 20 patients with 
progressive SSe reported that 16 (80%) of the 
patients had some form of cardiovascular 
complications and abnormalities on 
electrocardiography (ECG) while 45% of them 
showed some kind of abnormality on 
echocardiography. 
Meuneet al22 studied 100 consecutive patients 
presenting with SSe without pulmonary 
arterial hypertension or clinical 
manifestations of heart failure. All patients 
underwent standard echocardiography. He 
reported that patients with SSe had a wider 
mean left atrial diameter, a smaller LV 
ejection fraction, higher pulmonary artery 
pressures and diastolic dysfunction as also 
seen in our patient. 
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In our patient the electrocardiogram showed 
sinus tachycardia with occasional premature 
ventricular complexes and inferolateral 
ischemia.The echocardiography showed 
dilatation of all four chambers with an 
Ejection fraction of 38%, grade III diastolic 
dysfunction, moderate mitral regurgitation 
and thickened pericardium. 
These features are in keeping with the 
findings of the studies from Kane et al20, Badui 
et ae1and Meune et ae2above and further 
confirm the evidence of primary cardiac 
complication of SSe in the reported case. 
These clinical manifestations of SSe cardiac 
disease reflect the underlying conditions of 
myocardial necrosis and fibrosis and may at 
times mimic ischemic heart disease due to 
atherosclerosis8'9 • If myocardial injury is 
extensive enough, it may lead to dilated 
hypodynamic ventricles and a syndrome 
resembling idiopathic dilated cardiomyopathy 
may be simulated as seen in our patient who 
had dilatation of all four cardiac chambers on 
echocardiography. 
In general, myocardial fibrosis is considered to 
be the hallmark of cardiac involvement in 
SSc1'4'8'18• The fibrosis which is patchy and 
involves all levels of the myocardium bears no 
direct relation to large or small vessel 
occlusion or other anatomic abnormalities4'8'9• 
Consequently all levels of the myocardium 
may be unpredictably involved with the right 
ventricle affected as often as the left. It is thus 
possible that the right ventricular 
involvement seen in this patient may be a 
result of this process and not a secondary event 
from pulmonary hypertension. 
Systolic and/or diastolic dysfunction can occur 
as a result of myocardial fibrosis but the role of 
ongoing low grade myocarditis in this process 
is less well characterized1 ' 4 ' 8 ' 19 • Overt 
congestive heart failure occurs in more 
advanced disease, but systolic dysfunction is 
often clinically occult. Diastolic dysfunction is 
found in more than half of patients with 
scleroderma, even in the absence of 
myocardial ischemia, as it correlates with the 
severity of cutaneous disease4'8• Our patient 
had significant systolic and diastolic 
dysfunction and extensive skin involvement in 
keeping with this association as earlier 
highlighted. 
The prevalence of atherosclerotic coronary 
artery disease is not increased in SSc1'4'8 • 
However, in patients with scleroderma and 
coronary disease, the likelihood of coronary 
vasospasm is significantly higher than in the 
general population. 1.4,8'18 It is possible that 
coronary involvement in scleroderma is not in 
the epicardial vessels, but rests in small 
arterial segments as coronary angiograms are 
normal in patients with exercise-induced 
perfusion defects suggesting that abnormal 
resistance to flow is at the level of the 





23.The patient in this report had features of 
inferolateral ischemia. 
Pericardia! abnormalities In scleroderma 
include fibrinous pericarditis, fibrous 
pericarditis, pericardia! adhesions, 
constrictive pericarditis and pericardia! 
effusions. 8 ' 24 Asymptomatic pericardia! 
effusions commonly occur in scleroderma and 
are frequently associated with pulmonary 
hypertension and may be the presenting 
feature of pulmonary hypertension in 
scleroderma. Large pericardia! effusions can 
lead to pericardia! tamponade and are a 
marker for poor outcome 8 ' 24 • If an 
inflammatory component is thought to be the 
cause of the effusion, immunosuppression 
therapy can markedly reduce the volume of 
the effusion8'24• Moreover, if clinical heart 
failure is present, the effusion can be reduced 
with diuresis8'24• There was evidence of 
pericardia! thickening in our patient in 
keeping with pericardia! fibrosis. 
Conduction defects and arrhythmias are seen 
frequently in scleroderma patients and are 
thought to be a result of fibrosis or ischemia of 
the conduction system. 4'5'8'18 The patient we 
presented had PVCs on the ECG. The 
conduction defects in patients with SSe are 
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significant as they have been linked with 
higher risk for sudden cardiac death which 
fi t . l hyth . 45818 may occur rom ven ncu ar arr m1as. · · · 
Prior studies using echocardiography as well 
as studies on autopsy samples have suggested 
a relatively minor valvular involvement in 
SSe. 4'5'8 Shortening of the chordae tendinae of 
the mitral valve, mitral valve prolapse, mitral 
and aortic regurgitation and mitral and 
tricuspid valvevegetation's have all been 
reported.4' 5'8The finding of mitral valve 
regurgitation in our patient is in keeping with 
the outcome of earlier studies. 
At present, no treatments have been 
demonstrated to alter the natural history of 
primary cardiac involvement in patients with 
SSe. 4,5,8,26 
Although there is limited evidence in respect of 
specific therapeutic options, treatment of early 
abnormalities with calcium channel blockers 
such as Nifedipine and Nicardipine; and 
angiotensin-converting enzyme inhibitors 
(Captopril) may improve myocardial 
microcirculation, perfusion and function25'26• 
Ameliorating damage through tight control of 
systemic hypertension and early aggressive 
management of pulmonary hypertension are 
obviously important to prevent secondary 
cardiac damage 4'8'26• 
Short-term treatment with the dual 
endothelin receptor antagonist bosentan has 
been shown to simultaneously improve 
myocardial perfusion and function. 26'27 It 
remains to be seen if long-term treatment 
might result in additional remodeling effects. 27 
When left ventricular function is impaired 
standard therapies such as ACE inhibition 
and vasodilating ~-adrenoceptor blockade (if 
tolerated)should be used aggressively. 8'26In 
addition implantable cardioverter 
defibrillators (ICDs) and cardiac 
resynchronization therapy (CRT) may be 
applied as indicated. 8'26 In patients with CCF 
and fluid retention diuretics can be used to 
improve symptoms and when patients 
presenting with acutely deteriorating cardiac 
failure and persistent troponin leakage, 
indicative of active myocarditis aggressive 
cytotoxic therapy and immunosuppressive 
therapy with can be administered until 
troponin negativity is achieved. 26 
The patient in this case was placed on 
standard heart failure regimen and steroids. 
She however presented in an acute and critical 
state and all the implemented remedies could 
not save the patient. 
The presence of clinical cardiac involvement in 
SSe is a harbinger of a poor prognosis28• 
Cardiac disease in SSe is associated with a 
70% mortality at 5 years28'29• In general, higher 
risk findings in patients with SSe include 
clinical heart failure, poor RV function, 
pulmonary arterial hypertension, low cardiac 
index, high right atrial pressure, and 
documented ventricular arrhythmia8'28• Most 
of these features of poor prognosis were 
present in our index case, who died in the 
course of treatment. 
CONCLUSION 
Cardiovascular manifestations are frequent 
but often latent in patients with SSe. This 
finding emphasizes the importance of routine 
cardiovascular work-up in all patients with 
scleroderma. 
We recommend that cardiovascular screening 
which should include ECG, echocardiography, 
chest radiograph and B-type natriuretic 
peptide concentrations should be done 
biannually inSSc patients, in order to 
anticipate the development of cardiac 
symptoms. 
Although there is limited evidence in respect of 
specific therapeutic options, treatment of early 
abnormalities with calcium channel blockers 
and angiotensin-converting enzyme inhibitors 
may improve myocardial perfusion and 
function 18• 
It is important to evaluate SScpatients with 
features of heart failure for primary cardiac 
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disease of SScwithout assumption that it is 
corpulmonale and other secondary causes of 
CCF. 
LIMITATION 
There is no photographic microscope in our 
centre. 
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